Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting Provided ...

Three presentations on BNT327 1, an investigational anti-PD-L1xVEGF-A antibody, will detail data from ongoing later-stage and potentially registrational clinical trials: An oral presentation will ...

Capsida will also present data from its potential best-in-class programs for Parkinson’s disease associated with GBA mutations (CAP-003 PD-GBA) and Friedreich’s ataxia (CAP-004), as well as ...

Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why ...

Data from the dose-escalation study of a phase I, multi-center, open-label trial (NCT05824663) demonstrated the promising safety and tolerability profiles of HBM1020 in patients with advanced ...

Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to ...

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified ...

MAINZ, Germany, May 27, 2025-- BioNTech SE will present clinical trial data from select pipeline candidates across the Company’ s diversified oncology portfolio at the American Society of ...

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for ...

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified oncology ...